Suppr超能文献

[长期质子泵抑制剂治疗与骨质疏松症。真的存在风险吗?]

[Long-term proton pump inhibitor therapy and osteoporosis. Is there a real danger?].

作者信息

Maléth József, Hegyi Péter

机构信息

Szegedi Tudományegyetem, Szent-Györgyi Albert Klinikai Központ, Általános Orvostudományi Kar I. Belgyógyászati Klinika, Szeged.

出版信息

Orv Hetil. 2013 Jun 30;154(26):1005-9. doi: 10.1556/OH.2013.29656.

Abstract

Proton pump inhibitors are widely used in the treatment of acid-related diseases because they are considered to be effective and safe. In the past 10 years the use of proton pump inhibitors increased by over three folds, which is not associated with the increased prevalence of acid-related diseases obviously. However, like any other drugs, they have potential side effects. In recent years many studies have been published about the correlation between long-term proton pump inhibitor therapy and the increase of bone fractures. Most studies showed that long-term proton pump inhibitor therapy moderately increased fracture risk. The underlying mechanisms of increased number of bone fractures are not clarified yet. However, chronic acid suppression caused by long-term proton pump inhibitor therapy may play a crucial role in decreased absorption of calcium and vitamin B12 and, therefore, indirectly affecting the bones resulting in a decrease of bone mineral density. The available data suggest that proton pump inhibitors should be used with caution in patients with increased risk of osteoporosis.

摘要

质子泵抑制剂因其有效性和安全性被广泛用于治疗酸相关性疾病。在过去十年中,质子泵抑制剂的使用增加了三倍多,这与酸相关性疾病患病率的明显增加并无关联。然而,与其他任何药物一样,它们也有潜在的副作用。近年来,许多关于长期使用质子泵抑制剂治疗与骨折增加之间相关性的研究已经发表。大多数研究表明,长期使用质子泵抑制剂治疗会适度增加骨折风险。骨折数量增加的潜在机制尚未阐明。然而,长期使用质子泵抑制剂治疗导致的慢性酸抑制可能在钙和维生素B12吸收减少中起关键作用,因此间接影响骨骼,导致骨密度降低。现有数据表明,骨质疏松风险增加的患者应谨慎使用质子泵抑制剂。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验